Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gemcitabine in Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer

Gemcitabine in Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer Am J Cancer 2005; 4 (5): 334-335 GUEST COMMENTARIES 1175-6357/05/0005-0334/$34.95/0 © 2005 Adis Data Information BV. All rights reserved. much controversy exists regarding the administration of combina- Gemcitabine in Combination with Paclitaxel tion chemotherapy versus single agents in metastatic breast cancer, in the First-Line Treatment of Metastatic one can not refute the results of the prospective phase III trial, Breast Cancer which endorse the gemcitabine plus paclitaxel combination as A Viewpoint by Denise A. Yardley first-line therapy for metastatic breast cancer. Response rates were Sarah Cannon Research Institute, Nashville, Tennessee, USA nearly doubled for patients treated with the combination and this correlated with improvements in their median time to disease The goals of systemic therapy for metastatic breast cancer are progression and, perhaps more importantly, their survival. More- to improve survival and to palliate symptoms. At best, this should over, these statistically significant results were not accompanied be accomplished with minimal toxicity. Although a multitude of by increased toxicity but were complemented by superior pallia- factors can affect response to chemotherapy, all variables must be considered when both therapeutic and palliative endpoints are tion and quality of life, a finding no other major trial to date has being evaluated. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Gemcitabine in Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer

American Journal of Cancer , Volume 4 (5) – Aug 10, 2012

Gemcitabine in Combination with Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer

Abstract

Am J Cancer 2005; 4 (5): 334-335 GUEST COMMENTARIES 1175-6357/05/0005-0334/$34.95/0 © 2005 Adis Data Information BV. All rights reserved. much controversy exists regarding the administration of combina- Gemcitabine in Combination with Paclitaxel tion chemotherapy versus single agents in metastatic breast cancer, in the First-Line Treatment of Metastatic one can not refute the results of the prospective phase III trial, Breast Cancer which endorse the gemcitabine plus paclitaxel...
Loading next page...
 
/lp/springer-journals/gemcitabine-in-combination-with-paclitaxel-in-the-first-line-treatment-1oUCYc40LF
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504050-00008
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2005; 4 (5): 334-335 GUEST COMMENTARIES 1175-6357/05/0005-0334/$34.95/0 © 2005 Adis Data Information BV. All rights reserved. much controversy exists regarding the administration of combina- Gemcitabine in Combination with Paclitaxel tion chemotherapy versus single agents in metastatic breast cancer, in the First-Line Treatment of Metastatic one can not refute the results of the prospective phase III trial, Breast Cancer which endorse the gemcitabine plus paclitaxel combination as A Viewpoint by Denise A. Yardley first-line therapy for metastatic breast cancer. Response rates were Sarah Cannon Research Institute, Nashville, Tennessee, USA nearly doubled for patients treated with the combination and this correlated with improvements in their median time to disease The goals of systemic therapy for metastatic breast cancer are progression and, perhaps more importantly, their survival. More- to improve survival and to palliate symptoms. At best, this should over, these statistically significant results were not accompanied be accomplished with minimal toxicity. Although a multitude of by increased toxicity but were complemented by superior pallia- factors can affect response to chemotherapy, all variables must be considered when both therapeutic and palliative endpoints are tion and quality of life, a finding no other major trial to date has being evaluated.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.